The Effect of Bevacizumab Pretreatment on the Choice of Endotamponade in Diabetic Tractional Retinal Detachment.
To evaluate the effect of preoperative intravitreal bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) injection on the choice of endotamponade at the end of surgery in patients who underwent pars plana vitrectomy (PPV) for diabetic tractional retinal detachment (DTRD). Seventy-eight patients who had DTRD with macular involvement and underwent PPV by a single surgeon from January 2012 to May 2015 were included. Complete ophthalmological examinations were evaluated at the baseline and during the postoperative follow-up period. The mean age was 55.58 years ± 9.31 years in bevacizumab group and 56.70 years ± 9.35 years in the non-bevacizumab group. Preoperative IVB injection was performed in 38 of 78 patients. The complications of intraoperative retinal bleeding and iatrogenic retinal tear were not seen in 26 patients within the bevacizumab group or in 12 patients within the non-bevacizumab group (P = .016). Silicone oil was used as endotamponade in 10 patients (26%) in the bevacizumab group and in 28 patients (70%) in the non-bevacizumab group. The use of silicone oil as endotamponade in the non-bevacizumab group was significantly greater than in the bevacizumab group (P = .039). IVB injection reduces the need for the use of silicone oil as endotamponade in the patients who underwent PPV for DTRD at the end of surgery. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:924-929.].